Orforglipron oral GLP-1: what the phase 3 data actually shows

What did @drdanilomelis actually say?

The caption tells most of the story here, because the transcript itself is garbled beyond usability, likely a failed auto-transcription of Portuguese audio. Based on what we can read, @drdanilomelis framed orforglipron as "a new oral option, with similar action to injectable medications like Mounjaro" and flagged that injectables still hold an edge. The core message: a pill-form GLP-1 receptor agonist is coming, and it works differently from semaglutide tablets.

That framing is broadly defensible. Orforglipron is a non-peptide small molecule GLP-1 receptor agonist, which means it does not need the same absorption workarounds as oral semaglutide (Rybelsus), which must be taken fasting with minimal water. The creator also gestured at appetite control, satiety, and metabolic effects, which is consistent with the drug's mechanism. The mention of Mounjaro as a comparator is reasonable for audience context, though it's worth noting tirzepatide is a dual GIP/GLP-1 agonist, not a pure GLP-1, so the comparison has limits.

Does the science back this up?

Yes, with important caveats around effect size and trial stage. Phase 2 data published in 2023 is genuinely encouraging, but phase 3 results are still being collected. This is not yet an approved drug.

The headline phase 2 result comes from Wharton et al. (2023, New England Journal of Medicine), which found orforglipron produced up to 14.7% mean body weight reduction over 36 weeks at the highest dose in adults with obesity or overweight. That is a meaningful number, landing in roughly the same territory as once-weekly semaglutide 2.4 mg (Wegovy) in STEP 1, which produced about 14.9% weight loss at 68 weeks (Wilding et al., 2021, NEJM). Side effect profiles look similar to other GLP-1 agonists, with nausea and vomiting being the most common, and discontinuation rates were dose-dependent. Importantly, orforglipron does not require refrigeration and has no food or water restrictions on dosing, which are real practical advantages over oral semaglutide.

What did they get wrong (or right)?

The creator got the mechanism right and the caution right. Giving credit where it's due: flagging that injectables still outperform orforglipron at this stage of evidence is an honest call that many influencer physicians skip.

The comparison to Mounjaro specifically needs a footnote, though. Tirzepatide targets both GLP-1 and GIP receptors. Orforglipron targets GLP-1 only. Calling them "similar" in action is close enough for a lay audience but glosses over a distinction that affects expected outcomes. Tirzepatide in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) hit up to 22.5% weight loss at 72 weeks, which is substantially higher than current orforglipron phase 2 data. Equating the two drugs without that context could set unrealistic expectations for patients hoping a pill will match a dual-agonist injectable. Also worth stating plainly: orforglipron is not approved by any regulatory agency as of mid-2025. No one should be asking their doctor for a prescription yet because there is no prescription to give.

What should you actually know?

Orforglipron is real, the early data is genuinely promising, and the oral delivery format solves real access problems. But this is a drug still in phase 3 trials, and the gap between phase 2 excitement and phase 3 reality is where many promising compounds have quietly disappeared.

The practical case for an oral non-peptide GLP-1 agonist is strong. Injectable GLP-1 drugs face global supply shortages, cold chain logistics problems, and needle-aversion barriers that limit who actually uses them. A pill that works comparably, even if not identically, would change access meaningfully. Eli Lilly is running the ATTAIN phase 3 program, with results expected in 2025 to 2026. Until those read out, any claim that orforglipron "works like Mounjaro" is an extrapolation from incomplete data. If you are currently on an injectable GLP-1 medication, do not switch based on social media previews of phase 2 data. Talk to your prescriber when and if this drug reaches approval.

Bottom line

This video gets more right than wrong. The mechanism is accurately described, the caution about injectables is appropriate, and the enthusiasm is proportionate to what phase 2 data actually showed. The Mounjaro comparison needed a harder qualification. The bigger issue is timing: framing a phase 2 drug as an imminent clinical option without clearly stating it is not yet approved could push patients to ask questions their doctors cannot yet answer with a prescription pad.